Industries > Pharma > Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027

Leading IVD Companies in the US, Europe and Asia

PUBLISHED: 18 November 2016
PAGES: 185
PRODUCT CODE: PHA0152
SUBMARKET: Medical Devices

Clear
WOOCS 2.2.1
SKU: PHA0152 Categories: , Tags: ,

What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain’s new report Medical Devices Leader Series – Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027.

Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.

Our report forecasts to 2027 the overarching IVD market and its main segments:
• Point-of-care (POC) tests
• Clinical chemistry
• Immunochemistry
• Haematological diagnostics
• Microbiological applications
• Genetic testing agents
• Other products

Medical Devices Leader Series

This report provides profiles, discussions and financial analyses – including revenue forecasts to 2027 – for top US IVD companies:
• Danaher
• Abbott Laboratories
• Johnson & Johnson (J&J)
• Bio-Rad
• Becton Dickinson
• Thermo Fisher Scientific

Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe:
• Roche
• Siemens
• bioMérieux

This report also provides outlooks and revenue forecasts to 2027 for top Japanese companies developing and producing IVD tests:
• Sysmex
• Arkray

Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations:
• Dako (Agilent Technologies)
• Genomic Health
• Laboratory Corporation of America (LabCorp)
• MDxHealth
• Myriad Genetics
• QIAGEN

Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia.

Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027


Latest Pharma news

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

READ

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

READ

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

READ

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

READ

Categories